Novel LSE-listed pharmaceutical company focused on pain relief: raising £10m of CLN’s and/ or equity to meet contractual commitments in UK/ EU and target US dual IPO in next 12~18 months. Expression of interest for £5m CLN paying 10% with terms, warranties/ options to be negotiated, also £1m of equity (already drawn). Strong demand for product – ~£80m of LOIs (diverse) with initial contracts signed and supply underway. $8bn of global opportunity today; projected $50bn by 2027, with high barriers to entry. Extensively licensed by UK Government – GMP, MHRA and Home Office Licencing; early mover in highly regulated market. Listed on London Stock Exchange @ £100m valuation (outperforming AIM All Share index by 33% since IPO)